By Fineline Cube 
China-based Innovent Biologics, Inc. (HKG: 1801) announced the dosing of the first participant in China for the Phase III GLORY-OSA study of its mazdutide (IBI362). This dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist targets patients with moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI≥28kg/m²). This marks the seventh Phase III study initiated for mazdutide.
Clinical Trial Significance
While positive airway pressure (PAP) remains the first-line therapy for OSA, adherence challenges persist. In December 2024, tirzepatide (Zepbound) became the first FDA-approved treatment for OSA and obesity. However, no pharmacotherapies with proven efficacy are available for OSA in China, highlighting the potential of mazdutide to address this unmet need.
Drug Mechanism
Mazdutide, co-developed with Eli Lilly, works by enhancing insulin secretion and glycemic control through GLP-1R agonism, while increasing energy expenditure and improving hepatic fat metabolism via GCGR agonism. This dual action positions mazdutide as a promising therapeutic option for patients with OSA and obesity.-Fineline Info & Tech